Show simple item record

dc.contributor.authorCavallo Marincola, Beatriceen
dc.contributor.authorTelesca, Mariannaen
dc.contributor.authorZaccagna, Fulvioen
dc.contributor.authorRiemer, Franken
dc.contributor.authorAnzidei, Micheleen
dc.contributor.authorCatalano, Carloen
dc.contributor.authorPediconi, Federicaen
dc.date.accessioned2018-07-31T14:11:45Z
dc.date.available2018-07-31T14:11:45Z
dc.date.issued2019-01en
dc.identifier.issn0284-1851
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/278590
dc.description.abstractBackground: The goals of neoadjuvant chemotherapy (NAC) are to reduce tumor volume and to offer a prognostic indicator in assessing treatment response. Contrast-enhanced Magnetic Resonance Imaging (CE-MRI) is an established method for evaluating response to NAC in patients with breast cancer. Purpose: To validate the role of unenhanced MRI (ue-MRI) compared to CE-MRI for assessing response to NAC in women with breast cancer. Material and methods: 71 patients with an ongoing NAC for breast cancer underwent MRI before, during and at the end of NAC. Ue-MRI was performed with T2 weighted sequence with iterative decomposition of water and fat and diffusion-weighted sequences. CE-MRI was performed using 3D T1-weighted sequences before and after administration of gadobenate dimeglumine. Two blinded observers rated ue-MRI and CE-MRI for the evaluation of tumor response. Statistical analysis was performed to compare lesion size and ADC values changes during therapy, as well as inter-observer agreement. Results: There were not statistically significant differences between ue-MRI and CE-MRI sequences for evaluation of lesion size at baseline and after every cycle of treatment (p>0.05). The mean tumor ADC values at baseline and across the cycles of NAC were significantly different for responder group. Conclusion: Ue-MRI can achieve similar results to CE-MRI for the assessment of tumor response to NAC. ADC values can differentiate responders from non-responders.
dc.format.mediumPrint-Electronicen
dc.languageengen
dc.publisherTaylor & Francis
dc.subjectBreasten
dc.subjectHumansen
dc.subjectBreast Neoplasmsen
dc.subjectMeglumineen
dc.subjectOrganometallic Compoundsen
dc.subjectContrast Mediaen
dc.subjectMagnetic Resonance Imagingen
dc.subjectImage Enhancementen
dc.subjectTreatment Outcomeen
dc.subjectChemotherapy, Adjuvanten
dc.subjectNeoadjuvant Therapyen
dc.subjectReproducibility of Resultsen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectMiddle Ageden
dc.subjectFemaleen
dc.titleCan unenhanced MRI of the breast replace contrast-enhanced MRI in assessing response to neoadjuvant chemotherapy?en
dc.typeArticle
prism.endingPage44
prism.issueIdentifier1en
prism.publicationDate2019en
prism.publicationNameActa radiologica (Stockholm, Sweden : 1987)en
prism.startingPage35
prism.volume60en
dc.identifier.doi10.17863/CAM.25928
dcterms.dateAccepted2018-04-01en
rioxxterms.versionofrecord10.1177/0284185118773512en
rioxxterms.versionAM*
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2019-01en
dc.contributor.orcidZaccagna, Fulvio [0000-0001-6838-9532]
dc.contributor.orcidRiemer, Frank [0000-0002-3805-5221]
dc.contributor.orcidPediconi, Federica [0000-0002-1432-2137]
dc.identifier.eissn1600-0455
rioxxterms.typeJournal Article/Reviewen
rioxxterms.freetoread.startdate2019-05-09


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record